SOR-C13

SOR-C13 is a novel, short synthetic peptide derived from the C-terminal region of soricidin, a peptide found in the saliva of the Northern Short-tailed Shrew. It acts as a highly specific inhibitor of the transient receptor potential cation channel vanilloid family member 6 (TRPV6), a calcium channel that is overexpressed in various solid tumor cancers. By binding to TRPV6 with high affinity and selectivity, SOR-C13 disrupts calcium influx into tumor cells, inhibiting activation of nuclear factor of activated T-cell (NFAT) transcription complex. This results in reduced calcium-dependent cancer cell proliferation and induction of apoptosis in TRPV6-overexpressing tumors. SOR-C13 has demonstrated antitumor activity in preclinical models and early clinical trials for ovarian and pancreatic cancers. The drug has been granted orphan drug status by the FDA for both indications. Developed and manufactured by Soricimed Biopharma. SOR-C13 is considered first-in-class as a highly selective TRPV6 inhibitor to enter human clinical trials for cancer therapy. It is administered intravenously and continues to be evaluated primarily for advanced solid tumors expressing TRPV6. No brand or trade names are currently reported.

Other names

UNII-C79B5A73C4UNII-C-79B5A73C4UNII-C 79B5A73C41187852-48-7